Intervention not reported
Adverse events (grade 3 or 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time to initiation of first subsequent therapy · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
MSKCC risk groups · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (OS) ‐ Network included 15 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
1 finding from 1 review
Intervention not reported
Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 10 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
1 finding from 1 review
Intervention not reported
IMDC risk group · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 5 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No studies included for any outcomes · women with endometriosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of pain · patients with pain associated with endometriosis
1 finding from 1 review
Relief of overall pain ‐ reported as pelvic pain ‐ 3 months · patients with pain associated with endometriosis
1 finding from 1 review
Relief of overall pain ‐ reported as dysmenorrhoea ‐ 6 months · patients with pain associated with endometriosis
1 finding from 1 review
Relief of overall pain ‐ reported as pelvic induration ‐ 6 months · patients with pain associated with endometriosis
1 finding from 1 review
Relief of overall pain ‐ reported as pelvic tenderness ‐ 6 months · patients with pain associated with endometriosis
1 finding from 1 review
No studies included with only low risk of bias · patients with pain associated with endometriosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
GnRHas vs gestrinone Percentage change values ‐ 12 months · Women with endometriosis, treated with GnRHas with effect on bone mineral density
2 findings from 1 review
GnRHas vs GnRHas in conjunction with calcium‐regulating agents Anterior‐posterior spine ‐ 12 months · Women with endometriosis, treated with GnRHas with effect on bone mineral density
1 finding from 1 review
GnRHas vs GnRHas in conjunction with calcium‐regulating agents Lateral spine ‐ 12 months · Women with endometriosis, treated with GnRHas with effect on bone mineral density
1 finding from 1 review
Relief of overall pain ‐ reported as pelvic pain ‐ 3 months · women with endometriosis
GnRHas may leads to higher relief of overall pain ‐ reported as pelvic pain ‐ 3 months compared with placebo (low certainty).
1 finding from 1 review